Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07437638
Active, not recruiting Observational

Clinical Efficacy and Survival Prediction Analysis of Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis

NCT07437638 · tracked via the Priya Life Science China tracker
Sponsor
The Second Affiliated Hospital of Chongqing Medical University
Phase
Observational
Started
2024-09-01
Last updated
2026-02-27

Condition(s) studied

Liver CirrhosisHepatic EncephalopathyTIPS

Study summary

This study aims to develop a practical tool for identifying cirrhotic patients at high risk of hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS) placement. A retrospective analysis will be conducted on medical records of 624 cirrhotic patients who underwent TIPS from 2011 to 2021. Statistical methods will be applied to screen preoperative routine indicators associated with post-TIPS hepatic encephalopathy risk. A predictive nomogram will be constructed incorporating the screened indicators to estimate individual preoperative risk. The predictive performance will be compared with conventional clinical scoring systems. This tool is intended to facilitate preoperative risk evaluation and targeted management of high-risk patients undergoing TIPS

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18-80 years, regardless of gender * Diagnosis of decompensated cirrhosis meeting clinical guidelines * Complete preoperative baseline data available, with regular postoperative follow-up for at least 3 months to assess endpoint events * Absence of absolute contraindications for TIPS Exclusion Criteria: * Age \< 18 or \> 80 years * Non-cirrhotic portal hypertension * Hepatocellular carcinoma or other systemic malignancies * Severe cardiopulmonary disease * Prior liver transplantation or portosystemic shunt surgery * Death or liver transplantation within 30 days post-TIPS * Missing key baseline data or loss to follow-up

Primary outcome measure(s)

  • Occurrence of hepatic encephalopathy within 3 months after TIPS — 3-month follow-up after TIPS
    The development of hepatic encephalopathy, diagnosed based on clinical assessment and medical records during follow-up outpatient visits or hospital readmissions within 3 months after the TIPS procedure. All HE cases in this study occurred within this period.

Trial sites (1)

FacilityCityRegionStatus
Chongqing Chongqing China

More The Second Affiliated Hospital of Chongqing Medical University trials in China

Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS Recruiting
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B) Recruiting
The Effect of General Anesthesia with Remimazolam and Propofol on Rhythmic State and Cognitive Function Starting soon
Underdilated-stent Technique Improves Post-TIPS Encephalopathy Recruiting
Effect of Ciprofol Injection on Postoperative Cognitive Function Active, not recruiting

Other trials for the same condition

Comparison of Underdilated Versus Standard TIPS in Preventing Variceal Rebleeding in Patients With Cirrhosis Recruiting
Sonazoid CEUS for Early HCC Surveillance Starting soon
Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis Starting soon
A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic Encephalopathy Starting soon
UDCA to Prevent Post-TIPS Hepatic Encephalopathy Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07437638 on ClinicalTrials.gov ↗ ← All trials in China